Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 196,87 € (+9,07 %). Medianen er 212,52 € (+17,74 %).

Køb	16
Behold	12
Sælg	2

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

ICON Public Limited Company faces shrinking moat and pricing pressure, prompting Marram exit

Marram Investment Management exited its position in ICON Public Limited Company (ICLR) at breakeven after concluding the company’s competitive moat is deteriorating faster than expected. The firm cited unhealthy industry dynamics and a lack of pricing power that may worsen as AI-enabled cost efficiencies push peers to cut prices. ICON closed at $169.55 on Sept. 21, 2026, with a market capitalization of $13.08 billion and a 52-week range of $66.57 to $203.91. » Mere på finance.yahoo.com
ICON plans bond issuance to refinance existing debt

ICON’s subsidiary ICON Investments Six Designated Activity Company intends to offer senior notes in a private placement with registration rights. The net proceeds are to be used to fully repay a bridge loan, to repay the secured first‑lien credit facility and to defease the outstanding secured first‑lien notes due 2027 (coupon 5.809%). The unsecured, senior notes will be guaranteed by ICON and offered to qualified institutional buyers under Rule 144A and outside the U.S. pursuant to Regulation S; completion of the offering is not guaranteed. » Mere på de.investing.com
ICON (ICLR) posts strong net book-to-bill; to resume buybacks after accounting clean-up

Oakmark highlighted ICON's strong bookings, sharply lower cancellations and a robust net book-to-bill in Q2, which could support accelerating revenue growth if sustained. The clinical research organization reported results in line with expectations, margins met guidance, and management expects further margin gains from ongoing initiatives. With its accounting review completed, ICON plans to resume share buybacks after the next quarter's earnings, and Oakmark views the company as a leading pure play in an industry with a long growth runway. » Mere på finance.yahoo.com
AI partnership with Anthropic boosts ICON stock ahead of quarterly results

ICON announced a multi-year collaboration with Anthropic to integrate the Claude models across the entire lifecycle of clinical trials into its AI platform Orbis. Four production capabilities are planned: site analysis and study planning, predictive monitoring of recruitment risks, protocol optimization, and ecosystem integration for customer access. The news strengthened the premarket rally (+5.3%) and complements ICON’s multi-vendor AI strategy ahead of the Q2 results tomorrow (Wall Street EPS consensus: around $2.56). » Mere på de.investing.com
ICON accelerates clinical trials through partnership with Anthropic

ICON and Anthropic are launching a multi-year collaboration to integrate Claude’s AI capabilities into ICON’s Orbis platform. Planned are four core functions: site analysis and study planning; predictive analytics for real-time detection of recruitment risks; protocol optimization to accelerate study start-up; and ecosystem integration for direct customer access to insights. Claude will be deployed enterprise-wide in a role-based manner (Claude Code, Claude for knowledge teams, Claude Science) to strengthen automation, productivity, and domain-specific agents for clinical workflows. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Icon en omsætning på 1,79 mia. € og et nettoresultat på 107,82 mio. €

(EUR)	september 2026	YoY
Omsætning	1,79 mia.	2,69 %
Bruttofortjeneste	350,85 mio.	9,70 %
Nettoresultat	107,82 mio.	5.272,95 %
EBITDA	275,18 mio.	72,84 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	13,53 mia. €
Antal aktier	74,92 mio.
Højeste/laveste i 52 uger	198,09 € - 60,20 €
Udbytte	Nej
Beta	1,19
P/E (PE Ratio)	34,14
PEG (PEG Ratio)	-1,61
K/I (PB Ratio)	1,68
P/S (PS Ratio)	1,82

Virksomhedsprofil

ICON Public Limited Company, en klinisk forskningsorganisation, leverer outsourcede udviklings- og kommercialiseringstjenester i Irland, resten af Europa, USA og internationalt. Virksomheden er specialiseret i strategisk udvikling, styring og analyse af programmer, der understøtter de forskellige faser i den kliniske udviklingsproces, fra valg af forbindelse til fase I-IV kliniske undersøgelser. Den tilbyder kliniske udviklingstjenester, herunder tidlig udvikling, patientrekruttering og -fastholdelse, strategi og analyse, sen-fase forskning, data- og teknologiløsninger samt konsulent- og analysetjenester. Virksomhedens kliniske udviklingstjenester omfatter også medicinsk billeddannelse, klinisk forskning og laboratorietjenester, projektledelse, monitorering og styring af undersøgelsessteder, datahåndtering, biostatistik og programmering, medicinsk skrivning og publicering, medicinske anliggender, endpoint-adjudikation/datamonitoreringskomiteer, farmakovigilans, interaktive responsteknologier, styring af kliniske forsyninger, strategisk regulering, medicinsk kommunikation samt konsulent- og rådgivningstjenester. Den betjener læmiddel-, bioteknologi- og medicinsk udstyrsindustrien samt offentlige myndigheder og folkesundhedsorganisationer. Virksomheden blev stiftet i 1990 og har hovedsæde i Dublin, Irland.